TATA Health International Holdings (HKSE:01255) Other Stockholders Equity: HK$17.36 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01255 TATA Health International Holdings Ltd HKSE:01255
22 GF Score
Price HK$2.17
GF Value HK$0.21
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is TATA Health International Holdings Other Stockholders Equity?

TATA Health International Holdings HKSE:01255 -1.14% 22 Other Stockholders Equity is HK$17.36 Mil as of Dec. 2025. GuruFocus rates HKSE:01255 with a GF Score™ of 22/100 and a GF Value™ of HK$0.21 (Significantly Overvalued). The stock has 8 warning signs investors should review.

TATA Health International Holdings's Other Stockholders Equity for the quarter that ended in Dec. 2025 was HK$17.36 Mil.

TATA Health International Holdings's quarterly Other Stockholders Equity declined from Dec. 2024 (HK$20.93 Mil) to Jun. 2025 (HK$15.91 Mil) but then increased from Jun. 2025 (HK$15.91 Mil) to Dec. 2025 (HK$17.36 Mil).

TATA Health International Holdings's annual Other Stockholders Equity increased from Dec. 2023 (HK$19.49 Mil) to Dec. 2024 (HK$20.93 Mil) but then declined from Dec. 2024 (HK$20.93 Mil) to Dec. 2025 (HK$17.36 Mil).

TATA Health International Holdings Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for TATA Health International Holdings's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TATA Health International Holdings Other Stockholders Equity Chart

TATA Health International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.58 17.67 19.49 20.93 17.36

TATA Health International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.49 20.93 20.93 15.91 17.36
HKSE:01255
22GF Score
TATA Health International Holdings Ltd HKSE:01255
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TATA Health International Holdings Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$17.36 Mil mean?
TATA Health International Holdings (HKSE:01255) has a Other Stockholders Equity of HK$17.36 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on TATA Health International Holdings and its competitors.
Is TATA Health International Holdings' Other Stockholders Equity too high?
TATA Health International Holdings' current Other Stockholders Equity is HK$17.36 Mil. Overall, TATA Health International Holdings has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TATA Health International Holdings' Other Stockholders Equity compare to NKE and DECK?
TATA Health International Holdings' Other Stockholders Equity of HK$17.36 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Manufacturing - Apparel & Accessories company?
A good Other Stockholders Equity depends on the Manufacturing - Apparel & Accessories industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on TATA Health International Holdings and its competitors. TATA Health International Holdings's current Other Stockholders Equity is HK$17.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TATA Health International Holdings stock overvalued right now?
Based on GuruFocus' analysis, TATA Health International Holdings (HKSE:01255) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.21, compared to a current price of HK$2.17 — trading 933.3% above its estimated fair value. The current Other Stockholders Equity is HK$17.36 Mil. TATA Health International Holdings' overall GF Score™ is 22/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For TATA Health International Holdings (HKSE:01255), the current Other Stockholders Equity is HK$17.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TATA Health International Holdings (HKSE:01255) Overvalued in 2026?

Based on GuruFocus' analysis, TATA Health International Holdings stock appears to be overvalued. The current stock price of HK$2.17 is trading 933.3% above its estimated GF Value™ of HK$0.21. GuruFocus considers TATA Health International Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:01255:

  • Other Stockholders Equity: HK$17.36 Mil
  • GF Value™: HK$0.21 vs. price of HK$2.17 (933.3% above fair value)
  • GF Score™: 22/100 with 8 warning signs

No single metric tells the full story. See the HKSE:01255 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TATA Health International Holdings Business Description

Address 15-33 Kwai Tak Street, Block 2, Flat F-J, 11th Floor, Kwai Tak Industrial Centre, Kwai Chung, New Territories, Hong Kong, HKG
TATA Health International Holdings Ltd is an investment holding company. Through its subsidiaries, the company operates in four segments: Trading of footwear products, Trading of healthcare products, Financial services, and Online medical services. The majority of its revenue comes from the Trading of footwear products. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from Macau.
22GF Score

Get the complete analysis for HKSE:01255

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.17
Price
HK$0.21
GF Value